GSK180 is a selective competitive inhibitor of kynurenine 3-monooxygenase (KMO; IC50: ~6 nM), an enzyme involved in tryptophan metabolism.

GSK180 inhibits endogenous KMO activity in primary human hepatocytes (IC50=2.6 μM) and it also inhibits rat KMO slightly less potently than the human enzyme (IC50=7 μM).

GSK180 is fit for i.v. management [1].

1799725-26-0

C10H7Cl2NO4

276.07

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years